Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition is a biopharmaceutical company making strides in the treatmentof neurodegenerative diseases, such as Alzheimer's. With a focus on commercializing its ZUNVEYL oral tablet formulation, the company is also exploring potential partnerships for other indications and formulations. Financially, the company beat analyst expectations with strong revenue and reduced future payment obligations, while also significantly strengthening its board with the addition of seasoned biotech executive Bethany Sensenig.

Bears say

Alpha Cognition is facing several challenges, including the potential difficulty in achieving sales traction for their drug, ZUNVEYL, and slow market uptake due to competition and pricing pressures. Despite their focus on differentiating themselves from existing treatments and targeting additional indications, their valuation of $500M may be too optimistic, and there are risks of setbacks in clinical testing and potential dilution in the future.

ACOG has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 4 analysts, ACOG has a Strong Buy consensus rating as of Jul 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.